CAS |
No.1022958-60-6(free base) |
英文名称 |
CEP-28122 mesylate salt |
分子式 |
C29H39ClN6O6S |
分子量 |
635.17 |
溶解性 |
Soluble in DMSO ≥0.1mg/mL(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
Solid |
储存条件 |
Powder: 2-8℃,2 years |
运输条件 |
冷藏运输 |
SMILES |
COC1=C(C=CC2=C1CCC(CC2)N3CCOCC3)NC4=NC=C(C(=N4)NC5C6CC(C5C(=O)N)C=C6)Cl.CS(=O)(=O)O |
InChIKey |
PIIIZYXUYVVFSN-WWQCAQLDSA-N |
InChI |
InChI=1S/C28H35ClN6O3.CH4O3S/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36;1-5(2,3)4/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34);1H3,(H,2,3,4)/t17-,18+,19+,23+,24-;/m1./s1 |
PubChem CID |
91885507 |
靶点 |
ALK |
通路 |
Protein Tyrosine Kinase/RTK;Angiogenesis |
背景说明 |
CEP-28122 mesylate salt 是一种高度有效的选择性的 ALK 抑制剂。 |
生物活性 |
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity[1]. |
In Vitro |
CEP-28122 mesylate salt(3-3000 nM; 48 hours)treatment leads to concentration-dependent growth inhibition of Karpas-299 and Sup-M2 cells in culture,associates with concentration-related caspase 3/7 activation.CEP-28122 mesylate salt(30-1000 nM; 2 hours)treatment leads to substantial suppression of phosphorylation of putative downstream effectors of ALK in Sup-M2 cells,indicating that the downstream signaling pathways are mediated by individual ALK fusion protein[1]. |
In Vivo |
CEP-28122 mesylate salt(3-30 mg/kg; oral gavage; twice a day; 12 days)produces dose-dependent antitumor activity in Sup-M2 subcutaneous tumor xenografts in SCID mice.In contrast,CEP-28122 has no antitumor activity in nu/nu mice bearing HCT116,suggesting that the antitumor activity of CEP-28122 in NPM-ALK–positive Sup-M2 tumor models is due to sustained NPM-ALK inhibition in tumors [1]. |
数据来源文献 |
[1]. Mangeng Cheng, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2012 Mar;11(3):670-9. |
规格 |
5mg |
单位 |
瓶 |